{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-25-000059","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.560165+00:00","generated_at":"2026-05-21T11:53:38.834749+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Incyte settles JAKAFI royalty dispute with Novartis; pays $280M vs $537M accrued","bullets":["Settlement resolves litigation over royalty duration under 2009 Collaboration and License Agreement.","Incyte to pay Novartis $280M; had $537.1M accrued as of March 31, 2025.","Royalty rate on future U.S. JAKAFI net sales reduced by 50% effective Jan 1, 2025.","Reduced royalty for Q1 2025 is ~$14.9M; $242.2M difference to be recorded in Q2 2025.","Settlement eliminates contingent liability and lowers future royalty expense."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-25-000059","json":"https://secwatch.observer/filing/0000879169-25-000059.json","markdown":"https://secwatch.observer/filing/0000879169-25-000059.md","text":"https://secwatch.observer/filing/0000879169-25-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000059/0000879169-25-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000059/incy-20250511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T11:53:38.834749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}